Greater diversity of the HIV-1 V3 neutralization domain in Tanzania compared with The Netherlands: serological and genetic analysis.
OBJECTIVE
To compare variation in the HIV-1 V3 neutralization domain in Tanzania and The Netherlands.


METHODS
For serologic analysis, the specificity of anti-V3 antibodies (immunoglobulin G) for a panel of V3 peptides was determined in sera from 55 symptomatic HIV-1-infected Tanzanians and 51 Dutch AIDS patients. For genetic analysis, viral RNA was isolated from 15 of the Tanzanian sera and six of the Dutch sera. The V3 encoding region was reverse-transcribed, polymerase chain reaction-amplified and bacterially cloned, and sequences were determined over a stretch of at least 207 nucleotides.


RESULTS
Thirty-five per cent of the Tanzanian sera, versus 2% of the Dutch sera, showed the highest reactivity to a V3 sequence of Zairian origin (RKSIHVGPGQAFYATG). Twenty-nine per cent of the Tanzanian sera, versus 82% of the Dutch sera, showed the highest reactivity to V3 sequences of US/European origin (RKSIXIGPGRAFYTTG; X = H, P or N). The Tanzanian RNA sequences showed greater diversity (mean distance, 19%) than the Dutch RNA sequences (10%). The measured anti-V3 specificities of the Tanzanian sera did not match accurately with the V3 sequences recovered from these sera. However, reactivity to the Zairian V3 peptide was associated with the sequence GPGQ, found in the centre of the V3 in 50% of the Tanzanian sequences. Sera from both countries that showed similar reactivities to the peptide panel contained RNA sequences that were relatively distant.


CONCLUSIONS
The diversity of the HIV-1 population in Tanzania is much greater than that in The Netherlands. An indication of the HIV-1 V3 variation in a particular geographic region can be obtained by serological methods, but sequence analysis should not be omitted.
Department of Virology, Academic Medical Centre, Amsterdam, The Netherlands.
G
G
Zwart
T F
TF
Wolfs
R
R
Bookelman
S
S
Hartman
M
M
Bakker
C A
CA
Boucher
C
C
Kuiken
J
J
Goudsmit
D000293:Adolescent; D000328:Adult; D000595:Amino Acid Sequence; D000918:Antibody Specificity; D005260:Female; D014644:Genetic Variation; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120 / Q000235:genetics*; D015658:HIV Infections / Q000382:microbiology*; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009426:Netherlands; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000235:genetics*; D010455:Peptides / Q000138:chemical synthesis / Q000235:genetics / Q000276:immunology; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D017386:Sequence Homology, Amino Acid; D013636:Tanzania
D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D010455:Peptides; D012367:RNA, Viral